Pluristem Initiates Final Validation Steps for New Manufacturing Facility

Pluristem Therapeutics PSTI announced today it has initiated the final validation steps for its new "state-of-the-art" manufacturing facility prior to taking possession of the facility. These steps include the validation of several installation systems including as heating, ventilation and air conditioning (HVAC), water, oil free air and sterile room systems. Zami Aberman, Chairman and CEO of Pluristem commented, "I am extremely proud of our team in meeting milestones for the completion of the world's first commercial cell therapy manufacturing facility. Assuming the PLX cells product candidates are successfully developed and approved by the regulators, we believe that the new facility would have the capacity to produce PLX cells for the treatment of over 150,000 patients annually estimated by Pluristem at $1 billion in production value. Additionally, as clinical trials are approved by regulators for additional indications, our new facility will enable us to supply PLX cells to conduct these trials in parallel." See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsGuidanceFinancingContractsManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!